# K111268

# 510(k) SUMMARY

Summary of $5 1 0 ( \mathbf { k } )$ safety and effectiveness in accordance with the requirements of 21 CFR $\ S 8 0 7 . 9 2$ .

<table><tr><td colspan="2" rowspan="1">Submitter Information.                     </td></tr><tr><td colspan="1" rowspan="1">Name</td><td colspan="1" rowspan="1">Bayer Healthcare LLC., Diabetes Care</td></tr><tr><td colspan="1" rowspan="1">Address</td><td colspan="1" rowspan="1">430 South Beiger StreetMishawaka IN46544USA</td></tr><tr><td colspan="1" rowspan="1">Phone number</td><td colspan="1" rowspan="1">(574) 257-3075</td></tr><tr><td colspan="1" rowspan="1">Fax number</td><td colspan="1" rowspan="1">(574) 256-3519</td></tr><tr><td colspan="1" rowspan="1">EstablishmentRegistrationNumber</td><td colspan="1" rowspan="1">1826988</td></tr><tr><td colspan="1" rowspan="1">Name of contactperson</td><td colspan="1" rowspan="1">Weiping Zhong</td></tr><tr><td colspan="1" rowspan="1">Date prepared</td><td colspan="1" rowspan="1">February 24 2012</td></tr><tr><td colspan="2" rowspan="1">Name of device                                        </td></tr><tr><td colspan="1" rowspan="1">Trade orproprietary name</td><td colspan="1" rowspan="1">Contour® NEXT EZ Blood Glucose Monitoring System</td></tr><tr><td colspan="1" rowspan="1">Common or usualname</td><td colspan="1" rowspan="1">Blood Glucose Monitoring System</td></tr><tr><td colspan="1" rowspan="1">Classification name</td><td colspan="1" rowspan="1">Glucose Test System</td></tr><tr><td colspan="1" rowspan="1">Classification panel</td><td colspan="1" rowspan="1">Clinical Chemistry and Clinical Toxicology</td></tr><tr><td colspan="1" rowspan="1">Regulation</td><td colspan="1" rowspan="1">21 CFR § 862.1345</td></tr><tr><td colspan="1" rowspan="1">Product Code(s)</td><td colspan="1" rowspan="1">LFR (Glucose Dehydrogenase, Glucose), NBW(System, Test, Blood Glucose, Over The Counter)</td></tr><tr><td colspan="1" rowspan="1">Legally marketeddevice(s) to whichequivalence is claimed</td><td colspan="1" rowspan="1">Contour Blood Glucose Monitoring System (K062058)</td></tr><tr><td colspan="1" rowspan="1">Reason for 510(k)submission</td><td colspan="1" rowspan="1">Modified test strips and measurement algorithm</td></tr><tr><td colspan="1" rowspan="1">Device description</td><td colspan="1" rowspan="1">The Contour NEXT EZ Blood Glucose MonitoringSystem consists of:1Contour NEXT EZ Blood Glucose MeterContour NEXT Blood Glucose Test Strips3. Contour NEXT Control Solutions</td></tr><tr><td colspan="1" rowspan="1">Intended use of thedevice</td><td colspan="1" rowspan="1">The Contour NEXT EZ Blood Glucose MonitoringSystem is intended to measure the glucoseconcentration in whole blood.</td></tr><tr><td colspan="2" rowspan="1">Indications for use</td><td colspan="2" rowspan="1">The CONTOUR NEXT EZ blood glucose monitoringsystem is an over the counter (OTC) device utilized forself-testing by persons with diabetes at home for thequantitative measurement of glucose in whole blood, isfor single-patient use only, and should not be shared.The CONTOUR NEXT EZ blood glucose monitoringsystem is indicated for use with fresh fingertip capillarywhole blood samples. The clinical utility of this deviceis to aid in monitoring the effectiveness of your diabetescontrol program.The CONTOUR NEXT EZ blood glucose monitoringsystem is not intended for use for the diagnosis of orscreening for diabetes mellitus and is not intended foruse on neonates.The CONTOUR NEXT test strips are intended for self-testing by persons with diabetes for the quantitativemeasurement of glucose in whole blood samples from20 to 600 mg/dL.The CONTOUR NEXT control solutions are aqueousglucose solutions intended for use in self-testing bypeople with diabetes as a quality control check.</td></tr><tr><td colspan="4" rowspan="1">Summary of the Technological Characteristics ofthe New Device Compared to Predicate               d9:</td></tr><tr><td colspan="4" rowspan="1">SIMILARITIES to Predicate</td></tr><tr><td colspan="1" rowspan="1">Characteristic</td><td colspan="2" rowspan="1">PredicateContour (K062058)</td><td colspan="1" rowspan="1">Contour NEXT EZ(Candidate Device)</td></tr><tr><td colspan="1" rowspan="1">Blood SampleVolume</td><td colspan="2" rowspan="1">0.6μL</td><td colspan="1" rowspan="1">Same as predicate</td></tr><tr><td colspan="1" rowspan="1">Meal Markers</td><td colspan="2" rowspan="1">Yes</td><td colspan="1" rowspan="1">Same as predicate</td></tr><tr><td colspan="1" rowspan="1">Automatic Calibration</td><td colspan="2" rowspan="1">Yes</td><td colspan="1" rowspan="1">Same as predicate</td></tr><tr><td colspan="1" rowspan="1">Communication Port</td><td colspan="2" rowspan="1">Serial Interface</td><td colspan="1" rowspan="1">Same as predicate</td></tr><tr><td colspan="1" rowspan="1">User Interface</td><td colspan="2" rowspan="1">Alphanumeric, Iconic</td><td colspan="1" rowspan="1">Same as predicate</td></tr><tr><td colspan="1" rowspan="1">Display (Technology)</td><td colspan="2" rowspan="1">LCD</td><td colspan="1" rowspan="1">Same as predicate</td></tr><tr><td colspan="1" rowspan="1">Operational Buttons</td><td colspan="2" rowspan="1">3</td><td colspan="1" rowspan="1">Same as predicate</td></tr><tr><td colspan="1" rowspan="1">Battery Type</td><td colspan="2" rowspan="1">Two CR2032 (3-Volt each)(or DL2032)</td><td colspan="1" rowspan="1">Same as predicate</td></tr><tr><td colspan="1" rowspan="1">Displayed CountdownTime</td><td colspan="2" rowspan="1">5 seconds</td><td colspan="1" rowspan="1">Same as predicate</td></tr><tr><td colspan="1" rowspan="1">Detection Technology</td><td colspan="2" rowspan="1">Amperometric measurementof blood glucose</td><td colspan="1" rowspan="1">Same as predicate</td></tr><tr><td colspan="1" rowspan="1">Reference method</td><td colspan="1" rowspan="1">Plasma equivalent</td><td colspan="1" rowspan="1">Same as predicate</td></tr><tr><td colspan="1" rowspan="1">Test Strip enzyme</td><td colspan="1" rowspan="1">FAD-Glucose Dehydrogenase</td><td colspan="1" rowspan="1">Same as predicate</td></tr><tr><td colspan="1" rowspan="1">Calibration/Coding</td><td colspan="1" rowspan="1">Autocoding (no coding forusers)</td><td colspan="1" rowspan="1">Same as predicate</td></tr><tr><td colspan="3" rowspan="1">DIFFERENCES from Predicate</td></tr><tr><td colspan="1" rowspan="1">Characteristic</td><td colspan="1" rowspan="1">PredicateContour (K062058)</td><td colspan="1" rowspan="1">Contour NEXT EZ(Candidate Device)</td></tr><tr><td colspan="1" rowspan="1">Mediator in test strip</td><td colspan="1" rowspan="1">Potassium Ferricyanide</td><td colspan="1" rowspan="1">MLB Mediator</td></tr><tr><td colspan="1" rowspan="1">Control Solutionbuffer concentration</td><td colspan="1" rowspan="1">50mM to 100 mM</td><td colspan="1" rowspan="1">22 mM</td></tr><tr><td colspan="1" rowspan="1">Control SolutionLevels and Ranges</td><td colspan="1" rowspan="1">Low / Normal / High</td><td colspan="1" rowspan="1">Low (Level 1)/ Normal(Level 2)</td></tr><tr><td colspan="1" rowspan="1">Applied voltageduring glucosemeasurement</td><td colspan="1" rowspan="1">Constant</td><td colspan="1" rowspan="1">Pulsed</td></tr><tr><td colspan="1" rowspan="1">Hematocrit range</td><td colspan="1" rowspan="1">0%-70%</td><td colspan="1" rowspan="1">15%-65%</td></tr><tr><td colspan="1" rowspan="1">Measurement range</td><td colspan="1" rowspan="1">10-600mg/dL</td><td colspan="1" rowspan="1">20-600 mg/dL</td></tr><tr><td colspan="1" rowspan="1">MeasurementReaction time</td><td colspan="1" rowspan="1">5 seconds</td><td colspan="1" rowspan="1">7 seconds</td></tr><tr><td colspan="1" rowspan="1">Sample type</td><td colspan="1" rowspan="1">Fresh fingertip capillarywhole blood samplesVenous whole blood samplesArterial whole blood samplesNeonatal blood samples</td><td colspan="1" rowspan="1">Fresh fingertip capillarywhole blood samples</td></tr><tr><td colspan="1" rowspan="1">Intended users</td><td colspan="1" rowspan="1">For home and professionaluses</td><td colspan="1" rowspan="1">For home use, single useronly</td></tr><tr><td colspan="1" rowspan="1">Double Dip"function</td><td colspan="1" rowspan="1">NoInadequate sample volumeresults in error message</td><td colspan="1" rowspan="1">YesSystem prompts for anadditional application ofblood in a certain timeframe when a underfilledblood sample is detected</td></tr></table>

!

<table><tr><td rowspan=1 colspan=6>PERFORMANCE DATA</td></tr><tr><td rowspan=1 colspan=6>SUMMARY OF NON-CLINICAL TESTS CONDUCTED FORDETERMINATION OF SUBSTANTIAL EQUIVALENCE</td></tr><tr><td rowspan=1 colspan=6>Performance Test Summary-New Device</td></tr><tr><td rowspan=1 colspan=1>Characteristic</td><td rowspan=1 colspan=5>Results Summary</td></tr><tr><td></td><td rowspan=7 colspan=5>System Accuracy Evaluation (ISO 15197 Section 7.3/7.4.1)Reference: 510(k) submission, Section - 001_015 SystemAccuracy (Book Additional Information 2)Protocol: Six Contour NEXT EZ meters, three lots of test strips and100 blood samples were tested in replicates. The first replicate (atotal of three hundred data points) was analyzed. Samples were alsotested in parallel on a YSI 2300 STAT PLUS glucose analyzer asreference valuesAcceptance Criteria: A minimum of 95 % of the individual glucoseresults shall fall within ± 15 mg/dL of the results obtained on the YSIanalyzer at glucose concentrations &lt; 75 mg/dL, and within ± 20 % atglucose concentrations ≥75 mg/dL.Results: All data (100%) fell within ±20% or ±15 mg/dL of thelaboratory comparison method. Further, the data show an improvedaccuracy in that 100% of test results fall within ±10 mg/dL(&lt;75mg/dL) and 99.2% fall within ±10% (≥ 75 mg/dL) of thelaboratory comparison method.Results                                  ±15 mg/dL±5 mg/dL  ±10 mg/dLwithin:YSI Glucose   49 of 51     51 of 51     51 of 51&lt;75 mg/dL   (96.1%)      (100%)      (100%)Results                                                      ±20%±5%        ±10%       ±15%within:YSI Glucose ≥  203 of 249   247 of 249   249 of 249   249 of 24975 mg/dL   (81.5%)      (99.2%)      (100%)       (100%)Results  ±5 mg/dL   ±10 mg/dL  ±15 mg/dL  ±15 mg/dLwithin:   or 5%      or 10%     or15%     or 20%252 of 300   298 of 300  300 of 300  300 of 300Total                    (99.3%)      (100%)      (100%).(84%)</td></tr><tr><td></td><td rowspan=1 colspan=1>Resultswithin:</td><td rowspan=1 colspan=1>±5 mg/dL</td><td rowspan=1 colspan=1>±10 mg/dL</td><td rowspan=1 colspan=1>±15 mg/dL</td></tr><tr><td></td><td rowspan=1 colspan=1>YSI Glucose&lt;75 mg/dL</td><td rowspan=1 colspan=1>49 of 51(96.1%)</td><td rowspan=1 colspan=1>51 of 51(100%)</td><td rowspan=1 colspan=1>51 of 51(100%)</td></tr><tr><td></td><td rowspan=1 colspan=1>Resultswithin:</td><td rowspan=1 colspan=1>±5%</td><td rowspan=1 colspan=1>±10%</td><td rowspan=1 colspan=1>±15%</td><td rowspan=1 colspan=1>±20%</td></tr><tr><td></td><td rowspan=1 colspan=1>YSI Glucose ≥75 mg/dL</td><td rowspan=1 colspan=1>203 of 249(81.5%)</td><td rowspan=1 colspan=1>247 of 249(99.2%)</td><td rowspan=1 colspan=1>249 of 249(100%)</td><td rowspan=1 colspan=1>249 of 249(100%)</td></tr><tr><td></td><td rowspan=1 colspan=1>Resultswithin:</td><td rowspan=1 colspan=1>±5 mg/dLor 5%</td><td rowspan=1 colspan=1>±10 mg/dLor 10%</td><td rowspan=1 colspan=1>±15 mg/dLor15%</td><td rowspan=1 colspan=1>±15 mg/dLor 20%</td></tr><tr><td></td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>252 of 300(84%)</td><td rowspan=1 colspan=1>298 of 300(99.3%)</td><td rowspan=1 colspan=1>300 of 300(100%)</td><td rowspan=1 colspan=1>300 of 300(100%).</td></tr><tr><td rowspan=1 colspan=1>Precision</td><td rowspan=1 colspan=5>Repeatability (ISO 15197 Section 7.2.2)Reference: 510(k) submission, Section Labeled PerformanceTesting - BenchProtocol: Venous blood was tested at five glucose concentrationranges: 30-50, 51-110, 111-150, 151-250 and 251-400mg/dL. Twooperators tested one lot of test strips on 10 meters with 10 replicates per</td></tr></table>

<table><tr><td rowspan=8 colspan=1></td><td rowspan=1 colspan=9>meter (n=100).Acceptance criteria: No ISO acceptance criterion established. Theinternal acceptance criterion was: Repeatability test must performwithin the established accuracy requirements of Cpk ≥ 0.65 (Cpk isdifference between the mean result and the nearest limit, divided by3 standard deviations.)Results: The following results show that all the Cpk values are greaterthan 0.65.</td></tr><tr><td rowspan=1 colspan=2>Interval</td><td rowspan=1 colspan=1>GrandMean</td><td rowspan=1 colspan=1>PooledSD</td><td rowspan=1 colspan=2>95% Cl ofSD</td><td rowspan=1 colspan=1>PooledVariance</td><td rowspan=1 colspan=1>Pooled%CV</td><td rowspan=1 colspan=1>CpK</td></tr><tr><td rowspan=1 colspan=2>1(30-50)</td><td rowspan=1 colspan=1>47.3</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=2>0.7-0.9</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>5.9</td></tr><tr><td rowspan=1 colspan=2>2(51-110)</td><td rowspan=1 colspan=1>84.2</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=2>1.0-1.2</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>4.6</td></tr><tr><td rowspan=1 colspan=2>3 (111-150)</td><td rowspan=1 colspan=1>138.5</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=2>1.9-2.3</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>4.1</td></tr><tr><td rowspan=1 colspan=2>4 (151-250)</td><td rowspan=1 colspan=1>201.5</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=2>2.4-2.9</td><td rowspan=1 colspan=1>7.0</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>4.5</td></tr><tr><td rowspan=1 colspan=2>5 (251-400)</td><td rowspan=1 colspan=1>326.3</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=2>4.6-5.5</td><td rowspan=1 colspan=1>25.1</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>3.7</td></tr><tr><td rowspan=1 colspan=2>EY</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=6 colspan=1>Linearity/assayreportablerange</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td rowspan=1 colspan=4>Regression equation</td><td rowspan=1 colspan=4>y = 0.967(x) + 1.246</td><td rowspan=1 colspan=1></td></tr><tr><td></td><td rowspan=1 colspan=4>95% Confidence Interval of Slope</td><td rowspan=1 colspan=4>0.964 to 0.970</td><td rowspan=1 colspan=1></td></tr><tr><td></td><td rowspan=1 colspan=4>95% Confidence Interval of Intercept</td><td rowspan=1 colspan=4>0.084 to 2.408</td><td rowspan=1 colspan=1></td></tr><tr><td></td><td rowspan=1 colspan=4>$r^2}$</td><td rowspan=1 colspan=4>0.998</td><td rowspan=1 colspan=1></td></tr><tr><td></td><td rowspan=1 colspan=4>Syx</td><td rowspan=1 colspan=4>9.86</td><td rowspan=1 colspan=1></td></tr></table>

<table><tr><td colspan="2"></td></tr><tr><td>Traceability</td><td>Reference: 510(k) submission, Section Labeled Performance Testing - Bench Contour NEXT EZ System are referenced to the Yellow Springs Instruments Stat Plus 2300 analyzer (YSI), which is traceable to the hexokinase method developed collaboratively by the FDA, CDC, NIST and AACC. The hexokinase method is incorporated in a Bayer procedure that utilizes NIST Standard Reference Material 917, dry D-glucose. Glucose serum controls from an outside supplier were characterized by Bayer using the hexokinase method as a reference. For each day that Bayer's YSI instruments were used as the reference method, the serum controls were analyzed to ensure that the instruments were in control.</td></tr><tr><td>Detection limit</td><td>Reference: 510(k) submission, Section Labeled Performance Testing - Bench In addition to the linearity study demonstrating that accurate readings are obtained throughout the reportable range between 20 and 600 mg/dL, the system was also tested with extremely low glucose (5 mg/dL) and extremely high glucose (900, 1200, 1500, and 1800 [mg/dL) to ensure that the Contour NEXT meter correctly reports "LO" and "HI" messages. Eight Contour meters (3 readings per [meter) were tested with three test strip lots. All 72 readings obtained with blood adjusted to 5 mg/dL glucose reported "LO", and all 288 readings obtained with blood adjusted to 900 mg/dL and higher reported "HI" Acceptance Criteria: For blood with extreme glucose levels, the acceptance criterion is for the meter to display "LO" or "HI" glucose error messages. Results: Pass. All extremely low and extremely high samples [generated "LO" or "HI" error messages as appropriate.</td></tr><tr><td>Analytical specificity</td><td>Reference: 510(k) submission, Section Labeled Performance Testing - Bench The hematocrit sensitivity of the Contour NEXT EZ System was evaluated with fresh venous blood samples ranging from 15% to 65% hematocrit. The plasma glucose concentrations were adjusted to 40 mg/dL and 550 mg/dL glucose. Twelve replicates per sample were collected on six Contour NEXT meters for each of the three lots of sensors. The results indicate that the assay bias is within 1Omg/dL (when sample glucose values &lt;100mg/dL) or 10% (when sample glucose values ≥100mg/dL) when compared to YSI references or to 40% Hct whole blood samples. The conclusion is that there is no trend of increasing assay</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">imprecision or bias by increasing sample hematocrit.Other potential interference substances were tested: Acetaminophen,Ascorbic Acid, Bilirubin, Cholesterol, Creatinine HCl, DopamineHCl, Galactose, Na Gentisate, Glutathione, Hemoglobin (g/dL),Ibuprofen (Na salt), L-Dopa, Maltose, Methyl Dopa, Na Salicylate,Tolazamide, Tolbutamide, Triglycerides, Uric Acid, XyloseIcodextrin, Caffeine, Ephedrine, and Tetracycline.It is shown that in the above substances, only xylose has a significanteffect over the range tested. Therefore, in the instruction for use, itindicates "Do not use during or soon after xylose absorption testing.Xylose in the blood will cause an interference."</td></tr><tr><td colspan="1" rowspan="1">Assay cut-off</td><td colspan="1" rowspan="1">Not applicable</td></tr><tr><td colspan="2" rowspan="1">SUMMARY OF CLINICAL TESTS CONDUCTED FOR DETERMINATIONOF SUBSTANTIAL EQUIVALENCE AND/OR OF CLINICALINFORMATION</td></tr><tr><td colspan="1" rowspan="1">Clinical study</td><td colspan="1" rowspan="1">Reference: 510(k) submission, Section 001_004 Clinical TrialsBook Additional Information 2)Protocol: A clinical study was conducted at a clinical site with 115subjects. Three lots of test strips were randomly assigned to thesubjects. The clinical performance of the Contour NEXT EZ Systemhas been demonstrated by comparing the results from the YSI labanalyzer and the HCP/User test results on the same fresh finger tipcapillary blood sample.Criteria: IS0 15197:2003 Section 8 does not establish the clinicaltrials acceptance criteria. The internal acceptance criteria are thatninety-five percent (95%) of the individual glucose results shall fallwithin ± 15 mg/dL of the results of the manufacturer's measurementprocedure at glucose concentrations &lt; 75 mg/dL and within ± 20 %at glucose concentrations ≥ 75 mg/dL.Results: All (100%) Contour NEXT results meet the above accuracyrequirements. Moreover, Contour NEXT results show that 100% ofresults fall within ±10 mg/dL at &lt;75 mg/dL and 96.3% fall within±10% at ≥ 75 mg/dL when tested by users on the same freshfingertip capillary blood sample, as shown in the following table.</td></tr></table>

<table><tr><td></td><td rowspan=1 colspan=1>Results within:</td><td rowspan=1 colspan=1>±5mg/dL</td><td rowspan=1 colspan=1>±10mg/dL</td><td rowspan=1 colspan=1>±15mg/dL</td><td></td></tr><tr><td></td><td rowspan=1 colspan=1>YSI Glucose &lt;75 mg/dL</td><td rowspan=1 colspan=1>6 of 7(85.7%)</td><td rowspan=1 colspan=1>7 of7(100.0%)</td><td rowspan=1 colspan=1>7 of7(100.0%)</td><td></td></tr><tr><td></td><td rowspan=1 colspan=1>Results within:</td><td rowspan=1 colspan=1>±5%</td><td rowspan=1 colspan=1>±10%</td><td rowspan=1 colspan=1>±15%</td><td rowspan=1 colspan=1>±20%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>YSI Glucose ≥75 mg/dL</td><td rowspan=1 colspan=1>83 of 108(76.9%)</td><td rowspan=1 colspan=1>104 of108(96.3%)</td><td rowspan=1 colspan=1>107 of108(99.1%)</td><td rowspan=1 colspan=1>108 of 108(100.0%)</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Combinedresults within:</td><td rowspan=1 colspan=1>. ±5mg/dL or5%</td><td rowspan=1 colspan=1>±10mg/dL or10%</td><td rowspan=1 colspan=1>±15mg/dL or15%</td><td rowspan=1 colspan=1>$±15 mg/dLor 20%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>89 of 115(77.4%)</td><td rowspan=1 colspan=1>111/115(96.5%)</td><td rowspan=1 colspan=1>114 of115(99.1%)</td><td rowspan=1 colspan=1>115 of 115(100.0%)Pa l</td></tr><tr><td rowspan=1 colspan=7>$m=r $CONCLUSIONS DRAWN FROM NON-CLINICAL AND CLINICAL DATA</td></tr><tr><td rowspan=1 colspan=7>The performance of the Contour NEXT EZ Blood Glucose Monitoring System issubstantially equivalent to the performance of the previously cleared Contour BloodGlucose Monitoring System (K062058).</td></tr></table>

Bayer Health Care LLC, Diabetes Care   
c/o Weiping Zhong   
Regulatory Affairs Specialist   
430 South Beiger Street   
Mishawaka, IN 46544, USA   
Re: k111268   
Trade/Device Name: Contour NEXT EZ Blood Glucose Monitoring System   
Regulation Number: 21 CFR 862.1345   
Regulation Name: Glucose Test System   
Regulatory Class: Class II   
Product Code: NBW, LFR, JJX   
Dated: February 24, 2012   
Received: February 27, 2012

Dear Sir/Madam:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

I yur device iscass eeabove)int iher class  (SpeilControls)o cass  A) it y be subject to such additional controls.Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Paits 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

This letter willallow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

Page 2

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/Medical   
Devices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance...

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm

Sincerely yours,

2L

Courtney H. Lias, Ph.D.   
Director   
Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostic Device .   
Evaluation and Safety   
Center for Devices and Radiological Health

Enclosure

# Indications for Use

510(k) Number (if known): K111268

Device Name: Contour NEXT EZ Blood Glucose Monitoring System

Indications For Use:

# Intended Use

The CONTOUR®NEXT EZ blood glucose monitoring system is an over the counter (OTC) device utilized for self-testing by persons with diabetes at home for the quantitative measurement of glucose in whole blood, is for single-patient use only, and should not be shared. The CONTOUR NEXT EZ blood glucose monitoring system is indicated for use with fresh fingertip capillary whole blood samples. The clinical utility of this device is to aid in monitoring the effectiveness of your diabetes control program.

The CONTOUR® NEXT EZ blood glucose monitoring system is not intended for use for the diagnosis of or screening for diabetes mellitus and is not intended for use on neonates.

The CONTOUR $\textsuperscript { \textregistered }$ NEXT test strips are intended for self-testing by persons with diabetes for the quantitative measurement of glucose in whole blood samples from 20 to 600 mg/dL.

The CONTOUR@NEXT control solutions are aqueous glucose solutions intended for use in self-testing by people with diabetes as a quality control check.

Prescription Use__X_And/Or (21 CFR Part 801 Subpart D)

Over the Counter Use X (21 CFR Part 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety OIVD)

![](images/336b1b4da4ca39d1bd132e08b82ef8354b488bc39c38ce2015a9e7c4f40b4524.jpg)

Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety

510(k) K11268